Sonoma Pharmaceuticals, Inc. Revenue Disclosure
NOTE 16 – Revenue Disaggregation
The Company generates product revenues from products which are sold into the human and animal healthcare markets, and the Company generates service revenues from laboratory testing services which are provided to medical device manufacturers.
The following table presents the Company’s disaggregated revenues by source:
| Year Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Product: | ||||||||
| Human Care | $ | 12,079,000 | $ | 10,110,000 | ||||
| Animal Care | 1,653,000 | 2,203,000 | ||||||
| Total Product Revenue | 13,732,000 | 12,313,000 | ||||||
| Service/Royalty | 556,000 | 422,000 | ||||||
| Total | $ | 14,288,000 | $ | 12,735,000 | ||||
The following table shows the Company’s revenues by geographic region:
| Year Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| United States | $ | 2,611,000 | $ | 3,058,000 | ||||
| Europe | 5,523,000 | 4,781,000 | ||||||
| Asia | 2,317,000 | 2,298,000 | ||||||
| Latin America | 2,962,000 | 1,726,000 | ||||||
| Rest of the World | 875,000 | 872,000 | ||||||
| Total | $ | 14,288,000 | $ | 12,735,000 | ||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Jun 17, 2025 | Showing above |
| 2024 | Jun 17, 2024 | |
| 2023 | Jun 21, 2023 | |
| 2022 | Jul 13, 2022 | |
| 2021 | Jul 14, 2021 | |
About Revenue Disclosures
Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.
Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.